TOP TEN perturbations for 39705_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39705_at
Selected probe(set): 39705_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39705_at (39705_at) across 6674 perturbations tested by GENEVESTIGATOR:
glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):2.6991158Number of Samples:2 / 4
| Experimental | glioma study 17 (glioblastoma; unsorted) |
| Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. | |
| Control | non-tumor cortical tissue |
| Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.2483091Number of Samples:3 / 3
| Experimental | glioma study 17 (glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):2.093256Number of Samples:2 / 4
| Experimental | glioma study 17 ( small cell glioblastoma; unsorted) |
| Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males. | |
| Control | non-tumor cortical tissue |
| Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.9085627Number of Samples:2 / 3
| Experimental | glioma study 17 (small cell glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.8356056Number of Samples:3 / 3
| Experimental | glioma study 17 (astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
Langerhans cell histiocytosis study 2 (multisystem) / Langerhans cell histiocytosis study 2 (multifocal)
Relative Expression (log2-ratio):1.8138123Number of Samples:2 / 2
| Experimental | Langerhans cell histiocytosis study 2 (multisystem) |
| Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland). | |
| Control | Langerhans cell histiocytosis study 2 (multifocal) |
| Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal (bone, skin lesions) disease. |
CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; glioblastoma, NOS; primary)
Relative Expression (log2-ratio):-1.7300615Number of Samples:2 / 3
| Experimental | CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted). | |
| Control | CNS cancer study 1 (PDX; glioblastoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioblastoma, NOS of the central nervous system (subcutaneously implanted). |
glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.7242966Number of Samples:2 / 3
| Experimental | glioma study 17 (anaplastic astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)
Relative Expression (log2-ratio):1.5667753Number of Samples:3 / 11
| Experimental | HCC study 20 (CDX; Hep-G2; ectopic) |
| Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks. | |
| Control | HCC study 20 (PDX; ectopic) |
| Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks. |
Langerhans cell histiocytosis study 3 / Langerhans cell histiocytosis study 4
Relative Expression (log2-ratio):-1.499074Number of Samples:10 / 7
| Experimental | Langerhans cell histiocytosis study 3 |
| CD3+ T-lymphocyte samples isolated from Langerhans cell histiocytosis (LCH) lesions in bone (8 cases) or skin (2 cases). Patient with different clinical status were included in this study (unifocal, single system; multifocal, single system and multifocal, multisystem disease). | |
| Control | Langerhans cell histiocytosis study 4 |
| CD3+ T-lymphocyte samples isolated from peripheral blood of patients with Langerhans cell histiocytosis, prior to chemotherapy treatment. Patient with different clinical status were included in this study (unifocal, single system and multifocal, single system disease). |